_Market.JPG)
Radionuclide Drug Conjugates (RDC) Market Size is predicted to witness a 13.9% of CAGR during the forecast period for 2024-2031.
Radionuclide Drug Conjugates (RDCs) represent a promising innovation in cancer treatment, utilizing a targeted approach to deliver radiation directly to tumor cells. By combining a radionuclide, targeting molecule, chelator, and linker, RDCs minimize harm to healthy tissues while effectively attacking cancer. This targeted delivery enhances precision and allows for simultaneous imaging and therapy, addressing both diagnosis and treatment needs.
One significant advantage of RDCs is their ability to circumvent drug resistance, a common hurdle in traditional cancer therapies. While conventional treatments often face resistance due to mutations in cancer pathways, RDCs leverage the direct DNA damage caused by radiation, which is less susceptible to such adaptations. This unique mechanism makes RDCs a compelling option for more effective cancer care.
The radionuclide drug conjugates (RDC) market is type, disease indication. By type the market is segmented into antibody radionuclide conjugates (ARC), peptide radionuclide conjugates (PRC), small molecular radionuclide conjugates (SMRC), CNS disorders, and other diseases. By disease indication the market is segmented into neuroendocrine tumors, prostate cancer, renal cell, carcinoma, others.
The Small Molecular Radionuclide Conjugates (SMRC) segment is significantly driving the Radionuclide Drug Conjugates (RDC) market due to several factors. Technological advancements have enabled the development of novel targeted therapies that utilize small molecules and peptides, enhancing therapeutic efficacy when coupled with radionuclides. Recent accelerated approvals, such as peptide drug conjugates and GalNac conjugates, have sparked increased interest in these innovative treatments, contributing to robust market growth. Clinical trials have demonstrated that SMRCs, like 177Lu-PSMA-617, exhibit high efficacy and safety, particularly in treating neuroendocrine tumors and prostate cancer, thereby boosting market demand. Additionally, strategic market entry focuses on leveraging the unique benefits of SMRCs, such as precise targeting and effective tumor cell killing, further propelling their competitive edge and commercial potential.
The Neuroendocrine Tumors segment is rapidly growing for Radionuclide Drug Conjugates (RDCs) due to several key factors. Notably, Novartis' Lutathera has demonstrated significant clinical efficacy in trials, improving patient outcomes for neuroendocrine tumors. Moreover, there is a substantial unmet need, as approximately 50% of carcinoid syndrome patients are at risk for fast-growing tumors, underscoring the demand for effective treatments. Regulatory approvals, including that from the FDA for several RDCs, further validate these therapies and enhance their availability. Additionally, manufacturers are strategically focusing on the unique advantages of RDCs, such as precise tumor targeting and effective cell killing, to establish a competitive edge in this market segment.
North America leads the Radionuclide Drug Conjugates (RDC) market due to a robust product pipeline and increased regulatory approvals for targeted cancer therapies, indicating a favorable environment for research and development. The region is known for its high adoption of innovative cancer treatments, particularly in the US, a trend expected to continue with RDCs. Additionally, the presence of major pharmaceutical companies like Novartis, Lantheus, and Curium Pharma strengthens this dominance. Coupled with a well-developed healthcare infrastructure that supports the commercialization of novel therapies, these factors position North America at the forefront of the RDC market.
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 13.9 % from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type, By Disease Indication and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
|
Competitive Landscape |
Telix Pharmaceuticals Limited, Grand Pharma, Bayer AG, Novartis AG, Lantheus, Curium Pharma, Yantai Lannacheng Biotechnology Co., Ltd, BoomRay Pharmaceuticals, Hengrui Medicine, Yunnan Baiyao Group, Sinotau, SmartNuclide Biopharma, Yuanda Pharmaceutical, Other Prominent Players |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Radionuclide Drug Conjugates (RDC) Market Snapshot
Chapter 4. Global Radionuclide Drug Conjugates (RDC) Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Pipeline Analysis
4.7. Industry Analysis – Porter’s Five Forces Analysis
4.8. Competitive Landscape & Market Share Analysis
4.9. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Type, Estimates & Trend Analysis
5.1. By Type, & Market Share, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the
5.2.1. Antibody Radionuclide Conjugates (ARC)
5.2.2. Peptide Radionuclide Conjugates (PRC)
5.2.3. Small Molecular Radionuclide Conjugates (SMRC)
Chapter 6. Market Segmentation 2: By Disease Indication Estimates & Trend Analysis
6.1. By Disease Indication & Market Share, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the
6.2.1. Neuroendocrine Tumors
6.2.2. Prostate Cancer
6.2.3. Renal Cell Carcinoma
6.2.4. Others
Chapter 7. Radionuclide Drug Conjugates (RDC) Market Segmentation 5: Regional Estimates &
Trend Analysis
7.1. North America
7.1.1. North America Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million)
estimates and forecasts By Type, 2019-2031
7.1.2. North America Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million)
estimates and forecasts By Disease Indication, 2019-2031
7.1.3. North America Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million)
estimates and forecasts by Country, 2019-2031
7.2. Europe
7.2.1. Europe Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million) By Type,
2019-2031
7.2.2. Europe Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million) By
Disease Indication, 2019-2031
7.2.3. Europe Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million) by
Country, 2019-2031
7.3. Asia Pacific
7.3.1. Asia Pacific Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million) By
Type, 2019-2031
7.3.2. Asia Pacific Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million) By
Disease Indication, 2019-2031
7.3.3. Asia Pacific Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million) by
Country, 2019-2031
7.4. Latin America
7.4.1. Latin America Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million) By
Type, (US$ Million) 2019-2031
7.4.2. Latin America Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million) By
Disease Indication, (US$ Million) 2019-2031
7.4.3. Latin America Radionuclide Drug Conjugates (RDC) Market revenue (US$ Million) by
Country, 2019-2031
7.5. Middle East & Africa
7.5.1. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market revenue (US$
Million) By Type, (US$ Million) 2019-2031
7.5.2. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market revenue (US$)
Million) By Disease Indication, (US$ Million) 2019-2031
7.5.3. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market revenue (US$
Million) by Country, 2019-2031
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Telix Pharmaceuticals Limited
8.2.2. Grand Pharma
8.2.3. Bayer AG
8.2.4. Novartis AG
8.2.5. Lantheus
8.2.6. Curium Pharma
8.2.7. Yantai Lannacheng Biotechnology Co., Ltd
8.2.8. BoomRay Pharmaceuticals
8.2.9. Hengrui Medicine
8.2.10. Yunnan Baiyao Group
8.2.11. Sinotau
8.2.12. SmartNuclide Biopharma
8.2.13. Yuanda Pharmaceutical
8.2.14. Other Prominent Players
Radionuclide Drug Conjugates (RDC) Market by Type -
Radionuclide Drug Conjugates (RDC) Market by Disease Indication -
Radionuclide Drug Conjugates (RDC) Market by Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
